{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:08:27Z","timestamp":1790856507933,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Empagliflozin (EMP) and sitagliptin (SIT) are antidiabetic agents with complementary mechanisms of action and are frequently formulated as fixed-dose combinations. However, their substantially overlapping ultraviolet absorption spectra limit the applicability of direct spectrophotometric determination in combined dosage forms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to develop and validate simple, rapid, and low-solvent-consumption ratio-manipulating spectrophotometric methods for simultaneous determination of EMP and SIT in combined pharmaceutical formulations, and to assess their analytical, environmental, and practical performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two mathematical spectrophotometric approaches, ratio difference (RD) and first-derivative ratio spectrophotometry (1DD), were developed. In the RD method, EMP was quantified using the amplitude difference between 230 and 285\u00a0nm, whereas SIT was determined from the amplitude difference between 257 and 209\u00a0nm. In the 1DD method, the first derivative of the ratio spectra was measured at 239\u00a0nm for EMP and 250\u00a0nm for SIT, using \u0394\u03bb\u2009=\u20098\u00a0nm and a scaling factor of 80. The methods were validated for linearity, accuracy, precision, selectivity, robustness, and sensitivity. Their environmental and practical profiles were assessed using the Carbon Footprint Reduction Index (CaFRI), Complex Modified Green Analytical Procedure Index (ComplexMoGAPI), Click Analytical Chemistry Index (CACI), Blue Applicability Grade Index (BAGI), and Whiteness Evaluation for Chemical Analysis (WECA) tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both methods were linear over concentration ranges of 2\u201325\u00a0\u00b5g\/mL for EMP and 5\u2013100\u00a0\u00b5g\/mL for SIT. For the RD method, the LOD values were 0.326 and 0.419\u00a0\u00b5g\/mL, and the LOQ values were 0.978 and 1.257\u00a0\u00b5g\/mL for EMP and SIT, respectively. For the 1DD method, the corresponding LOD values were 0.324 and 0.423\u00a0\u00b5g\/mL, while LOQ values were 0.972 and 1.269\u00a0\u00b5g\/mL for EMP and SIT, respectively. Mean recoveries ranged from 99.18% to 100.11%, with repeatability and intermediate-precision %RSD values not exceeding 0.761% and 0.979%, respectively. The proposed methods were successfully applied to commercial combined tablets, using ethanol as the analytical solvent. Student\u2019s t- and F-tests revealed no significant difference between the proposed and reported methods at the 95% confidence level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The developed RD and 1DD methods provide rapid, separation-free, and reliable alternatives for simultaneous spectrophotometric determination of EMP and SIT. Their use of ethanol, minimal sample preparation, low solvent consumption, and favorable analytical, environmental, and practical profiles support their suitability for routine pharmaceutical quality-control analysis, particularly in laboratories with limited chromatographic resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13065-026-01935-6","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:12:37Z","timestamp":1790853157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Green ratio-manipulating spectrophotometric methods for simultaneous determination of empagliflozin and sitagliptin in pharmaceutical formulations"],"prefix":"10.1186","volume":"20","author":[{"given":"Ahmad A. A.","family":"Mohamad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Almrasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Abdelazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"3","key":"1935_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ijms26031094","volume":"26","author":"E M\u0142ynarska","year":"2025","unstructured":"M\u0142ynarska E, Czarnik W, Dzie\u017ca N, J\u0119draszak W, Majchrowicz G, Prusinowski F, et al. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025;26(3):1094. https:\/\/doi.org\/10.3390\/ijms26031094.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1935_CR2","first-page":"V","volume":"1","author":"SA Tabish","year":"2007","unstructured":"Tabish SA, J. I. Is diabetes becoming the biggest epidemic of the twenty-first century? Int J Health Sci. 2007;1(2):V.","journal-title":"Int J Health Sci"},{"issue":"10","key":"1935_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrendo.2016.105","volume":"12","author":"P Zimmet","year":"2016","unstructured":"Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. J Nat Rev Endocrinol. 2016;12(10):616\u201322. https:\/\/doi.org\/10.1038\/nrendo.2016.105.","journal-title":"J Nat Rev Endocrinol"},{"key":"1935_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-1542-7","volume-title":"Diabetes mellitus in 21st century","author":"S Sen","year":"2016","unstructured":"Sen S, Chakraborty R, De B. Diabetes mellitus in 21st century. Springer; 2016."},{"issue":"7","key":"1935_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","volume":"16","author":"JB Cole","year":"2020","unstructured":"Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377\u201390. https:\/\/doi.org\/10.1038\/s41581-020-0278-5.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"1935_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. J Nat Rev Endocrinol. 2022;18(9):525\u201339. https:\/\/doi.org\/10.1038\/s41574-022-00690-7.","journal-title":"J Nat Rev Endocrinol"},{"key":"1935_CR7","doi-asserted-by":"publisher","DOI":"10.21608\/jbaar.2024.382794","author":"AAJJB Yameny","year":"2024","unstructured":"Yameny AAJJB, Research A. Diabetes mellitus overview 2024. JBAAR. 2024. https:\/\/doi.org\/10.21608\/jbaar.2024.382794.","journal-title":"JBAAR"},{"key":"1935_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1243-1","author":"RA Blair","year":"2016","unstructured":"Blair RA. Diabetes mellitus review. Curr Diabetes Rep. 2016. https:\/\/doi.org\/10.1007\/s11892-019-1243-1.","journal-title":"Curr Diabetes Rep"},{"issue":"8","key":"1935_CR9","first-page":"56","volume":"15","author":"SD Punyaprediwar","year":"2025","unstructured":"Punyaprediwar SD, Hashmi NAJEJCM. Evaluating the Efficacy and Safety of Combined Drug Therapy for Type II Diabetes Mellitus Patients: A Randomized Controlled Trial of Empagliflozin versus Sitagliptin as Add-on to Metformin. EJCM. 2025;15(8):56.","journal-title":"EJCM"},{"issue":"2","key":"1935_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1139\/cjpp-2021-0399","volume":"100","author":"E Gronda","year":"2022","unstructured":"Gronda E, Lopaschuk GD, Arduini A, Santoro A, Benincasa G, Palazzuoli A, et al. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. J Physiol Pharmacol. 2022;100(2):93\u2013106. https:\/\/doi.org\/10.1139\/cjpp-2021-0399.","journal-title":"J Physiol Pharmacol"},{"key":"1935_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10741-021-10079-9","volume":"27","author":"M Nikolic","year":"2022","unstructured":"Nikolic M, Zivkovic V, Jovic JJ, et al. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Fail Rev. 2022;27:935\u201349. https:\/\/doi.org\/10.1007\/s10741-021-10079-9.","journal-title":"Heart Fail Rev"},{"issue":"10","key":"1935_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJJD. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317. https:\/\/doi.org\/10.1007\/s00125-018-4670-7.","journal-title":"Diabetologia"},{"issue":"11","key":"1935_CR13","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178","volume":"60","author":"Barnett","year":"2006","unstructured":"Barnett, AJIjocp. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454\u201370. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01178.","journal-title":"Int J Clin Pract"},{"key":"1935_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","volume":"10","author":"BJ Gallwitz","year":"2019","unstructured":"Gallwitz BJ. Clinical use of DPP-4 inhibitors. Front Endocrinol. 2019;10:389. https:\/\/doi.org\/10.3389\/fendo.2019.00389.","journal-title":"Front Endocrinol"},{"key":"1935_CR15","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202308_33300","author":"H Zakaraia","year":"2023","unstructured":"Zakaraia H, Salem H, Mostafa M, Ali A, Rabea H. Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial. Eur Rev Med Pharmacol Sci. 2023. https:\/\/doi.org\/10.26355\/eurrev_202308_33300.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"1935_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5958\/2231-5675.2017.00004.7","volume":"7","author":"SD Patil","year":"2017","unstructured":"Patil SD, Chaure SK, Rahman MAH, Varpe PU, Kshirsagar SJA. Development and validation of simple UV-spectrophotometric method for the determination of Empagliflozin. Asian J Pharm Anal. 2017;7(1):18\u201322. https:\/\/doi.org\/10.5958\/2231-5675.2017.00004.7.","journal-title":"Asian J Pharm Anal"},{"issue":"2","key":"1935_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10812-024-01734-8","volume":"91","author":"S Sahu","year":"2024","unstructured":"Sahu S, Pandey RK, Shukla SS, Gidwani BJ. Spectrophotometric method development and validation of empagliflozin in active pharmaceutical ingredient and tablet dosage form. J Appl Spectrosc. 2024;91(2):405\u201310. https:\/\/doi.org\/10.1007\/s10812-024-01734-8.","journal-title":"J Appl Spectrosc"},{"key":"1935_CR18","doi-asserted-by":"publisher","first-page":"118307","DOI":"10.1016\/j.saa.2020.118307","volume":"235","author":"MA Omar","year":"2020","unstructured":"Omar MA, Ahmed HM, Batakoushy HA, Hamid MAA. New spectrofluorimetric analysis of empagliflozin in its tablets and human plasma using two level full factorial design. J Spectrochim Acta Mol Biomol Spectrosc. 2020;235:118307. https:\/\/doi.org\/10.1016\/j.saa.2020.118307.","journal-title":"J Spectrochim Acta Mol Biomol Spectrosc"},{"key":"1935_CR19","first-page":"28","volume":"5","author":"FM Salama","year":"2018","unstructured":"Salama FM, Attia KA, Abouserie AA, Mabrouk RA, Abdelzaher AM. Spectrofluorimetric estimation of empagliflozin in the presence of its oxidative degradation product. Eur J Biomed Pharm Sci. 2018;5:28\u201333.","journal-title":"Eur J Biomed Pharm Sci"},{"issue":"5","key":"1935_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/bio.3491","volume":"33","author":"MF Abdel-Ghany","year":"2018","unstructured":"Abdel-Ghany MF, Ayad MF, Tadros MM. Liquid chromatographic and spectrofluorimetric assays of empagliflozin: applied to degradation kinetic study and content uniformity testing. J Lumin. 2018;33(5):919\u201332. https:\/\/doi.org\/10.1002\/bio.3491.","journal-title":"J Lumin"},{"key":"1935_CR21","doi-asserted-by":"publisher","first-page":"9983477","DOI":"10.1155\/2021\/9983477","volume":"1","author":"B Ayoub","year":"2021","unstructured":"Ayoub B, El Zahar N, Michel H, Tadros MJ. Economic spectrofluorometric bioanalysis of empagliflozin in rats\u2019 plasma. J Anal Methods Chem. 2021;1:9983477. https:\/\/doi.org\/10.1155\/2021\/9983477.","journal-title":"J Anal Methods Chem"},{"issue":"10","key":"1935_CR22","doi-asserted-by":"publisher","first-page":"e4917","DOI":"10.1002\/bio.4917","volume":"39","author":"DH Rushdy","year":"2024","unstructured":"Rushdy DH, Atia NN, Ali MF, El-Gizawy SM. A Highly Sensitive Inclusion Complex Based Spectrofluorimetric Method for the Determination of Certain Sodium Glucose Cotransporter\u20102 Inhibitors: Greenness Assessment and Application to Different Biological Fluids. J Lumin. 2024;39(10):e4917. https:\/\/doi.org\/10.1002\/bio.4917.","journal-title":"J Lumin"},{"issue":"8","key":"1935_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/bio.4526","volume":"38","author":"NM Hosny","year":"2023","unstructured":"Hosny NM, GadAllah MI, Qayed WS. Combined experimental\/computational aspects for the molecular interaction of empagliflozin with bovine serum albumin: quantification and application to human plasma. J Lumin. 2023;38(8):1449\u201357. https:\/\/doi.org\/10.1002\/bio.4526.","journal-title":"J Lumin"},{"key":"1935_CR24","doi-asserted-by":"publisher","first-page":"122715","DOI":"10.1016\/j.saa.2023.122715","volume":"296","author":"IM Nour","year":"2023","unstructured":"Nour IM, Mohamed AR, Hasan MA, Badrawy M. Eco-friendly-assessed micellar-fluorimetric platform for concurrent analysis of empagliflozin and prucalopride succinate in biological fluids: docking simulation. J Spectrochim Acta Mol Biomol Spectrosc. 2023;296:122715. https:\/\/doi.org\/10.1016\/j.saa.2023.122715.","journal-title":"J Spectrochim Acta Mol Biomol Spectrosc"},{"key":"1935_CR25","doi-asserted-by":"publisher","first-page":"119258","DOI":"10.1016\/j.saa.2020.119258","volume":"248","author":"MS Elmasry","year":"2021","unstructured":"Elmasry MS, Hasan MA, Hassan WS, Merey HA, Nour IM. Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma. J Spectrochim Acta Mol Biomol Spectrosc. 2021;248:119258. https:\/\/doi.org\/10.1016\/j.saa.2020.119258.","journal-title":"J Spectrochim Acta Mol Biomol Spectrosc"},{"issue":"5","key":"1935_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.22159\/ijap.2019v11i5.33281","volume":"11","author":"M Basak","year":"2019","unstructured":"Basak M, Gouru SR, Bera A, Nagappan KVJ. I. A rapid and sensitive RP-HPLC method for the quantitative analysis of empagliflozin in bulk and pharmaceutical dosage form. Int J Appl Pharm. 2019;11(5):60\u20135. https:\/\/doi.org\/10.22159\/ijap.2019v11i5.33281.","journal-title":"Int J Appl Pharm"},{"issue":"6","key":"1935_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/chromsci\/bmaa129","volume":"59","author":"SL Burin","year":"2021","unstructured":"Burin SL, Louren\u00e7o RL, Doneda M, M\u00fcller EI, Paula FR, Adams AIHJ. Development of an HPLC-UV method to assay empagliflozin tablets and identification of the major photoproduct by quadrupole time-of-flight mass spectrometry. J Chromatogr Sci. 2021;59(6):526\u201335. https:\/\/doi.org\/10.1093\/chromsci\/bmaa129.","journal-title":"J Chromatogr Sci"},{"issue":"23B","key":"1935_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.9734\/JPRI\/2022\/v34i23B35926","volume":"34","author":"AV Gaikwad","year":"2022","unstructured":"Gaikwad AV, Khulbe PJ. HPLC method development for the estimation of empagliflozin in bulk and pharmaceutical formulation. J Pharm Res Int. 2022;34(23B):22\u201331. https:\/\/doi.org\/10.9734\/JPRI\/2022\/v34i23B35926.","journal-title":"J Pharm Res Int"},{"issue":"3","key":"1935_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.36721\/PJPS.2021.34.3.SUP.1081-1087.1","volume":"34","author":"AM Hanif","year":"2021","unstructured":"Hanif AM, Bushra R, Ismail NE, Bano R, Abedin S, Alam S,. ARIF MJP, Empagliflozin. HPLC based analytical method development and application to pharmaceutical raw material and dosage form. J Med Sci. 2021;34(3):1081\u20137. https:\/\/doi.org\/10.36721\/PJPS.2021.34.3.SUP.1081-1087.1.","journal-title":"J Med Sci"},{"issue":"1","key":"1935_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s43094-021-00329-w","volume":"7","author":"S Pathak","year":"2022","unstructured":"Pathak S, Mishra PJF. Stability-indicating HPLC-DAD method for the determination of empagliflozin. FJPS. 2022;7(1):181. https:\/\/doi.org\/10.1186\/s43094-021-00329-w.","journal-title":"FJPS"},{"issue":"10","key":"1935_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/separations9100275","volume":"9","author":"EY Santali","year":"2022","unstructured":"Santali EY, Naguib IA, Alshehri AM, Alzahrani YA, Alharthi AE, Alosaimi TS, Abourehab MA. Greenness assessment of chromatographic methods used for analysis of empagliflozin: a comparative study. J Sep. 2022;9(10):275. https:\/\/doi.org\/10.3390\/separations9100275.","journal-title":"J Sep"},{"issue":"1","key":"1935_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21276\/ijpbs.2019.9.1.4","volume":"9","author":"V Shirisha","year":"2019","unstructured":"Shirisha V, Bolle K, Santosh I, Rao K, Rajeswar DJ. I. A new simple method development, validation and forced degradation studies of empagliflozin by using Rp-Hplc. Int J Pharm Biol Sci. 2019;9(1):25\u201335. https:\/\/doi.org\/10.21276\/ijpbs.2019.9.1.4.","journal-title":"Int J Pharm Biol Sci"},{"issue":"7","key":"1935_CR33","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.20959\/wjpr20177-8741","volume":"6","author":"SH Jaiswal","year":"2017","unstructured":"Jaiswal SH, Katariya M, Katariya V, Karva G, Koshe KJWJPR. Validated stability indicating HPLC method for determination of process related impurities in empagliflozin drug substances. World J Pharm Res. 2017;6(7):1025\u201337.","journal-title":"World J Pharm Res"},{"key":"1935_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2025.112730","volume":"209","author":"NF El Azab","year":"2025","unstructured":"El Azab NF, Alqirsh SM, Magdy N, Abdel-Ghany MF. Enhanced sensitivity in empagliflozin detection: a voltammetric sensor with molecularly imprinted graphite film for analyzing pharmaceuticals and biological fluids. Microchem J. 2025;209:112730. https:\/\/doi.org\/10.1016\/j.microc.2025.112730.","journal-title":"Microchem J"},{"issue":"6","key":"1935_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/22297928.2018.1545603","volume":"8","author":"RM Ahmed","year":"2018","unstructured":"Ahmed RM, Hadad GM, El-Gendy AE, Ibrahim A. Development of HPLC method for determination of sitagliptin in human plasma using fluorescence detector by experimental design approach. J Anal Chem Lett. 2018;8(6):813\u201328. https:\/\/doi.org\/10.1080\/22297928.2018.1545603.","journal-title":"J. Anal. Chem. Lett."},{"issue":"1","key":"1935_CR36","first-page":"33194","volume":"32","author":"MK Qassas","year":"2015","unstructured":"Qassas MK, Ameral-mardini M, Ghazal HJI. A validated HPLC stability indicating method for the determination of sitagliptin in bulk drug substance and tablets. Int J Pharm Sci Rev Res. 2015;32(1):33194\u2013119.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"5","key":"1935_CR37","first-page":"407","volume":"76","author":"P Ramalingam","year":"2014","unstructured":"Ramalingam P, Bhaskar VU, Reddy YP, Kumar KV. J. I. Stability-indicating RP-HPLC method for the simultaneous determination of sitagliptin and simvastatin in tablets. Indian J Pharm Sci. 2014;76(5):407.","journal-title":"Indian J Pharm Sci"},{"issue":"10","key":"1935_CR38","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2298\/JSC141227046R","volume":"80","author":"R Rezaee","year":"2015","unstructured":"Rezaee R, Qomi M, Piroozi F. Hollow-fiber micro-extraction combined with HPLC for the determination of sitagliptin in urine samples. J Serb Chem Soc. 2015;80(10):1311\u201320. https:\/\/doi.org\/10.2298\/JSC141227046R.","journal-title":"J Serb Chem Soc"},{"issue":"9","key":"1935_CR39","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.13040\/IJPSR.0975-8232.4(9).3494-03","volume":"4","author":"DP Sonune","year":"2013","unstructured":"Sonune DP, Mone MK, J. I. Isolation, characterization of degradation products of sitagliptin and development of validated stability-indicating HPLC assay method for sitagliptin API and tablets. Int J Pharm Sci Res. 2013;4(9):3494\u2013503. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.4(9).3494-03.","journal-title":"Int J Pharm Sci Res"},{"issue":"7","key":"1935_CR40","first-page":"702","volume":"2","author":"N Disha","year":"2015","unstructured":"Disha N, Gurupadhayya BJIJIS. Engineering, Technology. Spectrophotometric determination of Sitagliptin phosphate in bulk and pharmaceutical formulations. IJISET. 2015;2(7):702\u20139.","journal-title":"IJISET"},{"issue":"3","key":"1935_CR41","first-page":"871","volume":"4","author":"P Pathade","year":"2011","unstructured":"Pathade P, Imran M, Bairagi V, Ahire YJJ. Development and validation of stability indicating UV spectrophotometric method for the estimation of sitagliptin phosphate in bulk and tablet dosage form. Pharm Res. 2011;4(3):871\u20133.","journal-title":"Pharm Res"},{"issue":"4","key":"1935_CR42","first-page":"194","volume":"3","author":"J Pritam","year":"2011","unstructured":"Pritam J, Amar C, Bhargav D, Shani P, Santsaran P, Hiren S, et al. Development and validation of first order derivative UV-Spectrophotometric method for determination of Sitagliptin in bulk and in formulation. Int J Drug Deliv Res. 2011;3(4):194\u20139.","journal-title":"Int J Drug Deliv Res"},{"key":"1935_CR43","first-page":"254","volume":"7","author":"P Ravisankar","year":"2014","unstructured":"Ravisankar P, Mounika G, Devadasu C, DevalaRao GJ. A simple validated UV Spectrophotometric method for quantitative analysis of Sitagliptin phosphate in pharmaceutical dosage form. J Chem Pharmaceut Sci. 2014;7:254.","journal-title":"J Chem Pharmaceut Sci"},{"key":"1935_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1590\/S0100-46702010000300003","volume":"35","author":"CB Sekaran","year":"2010","unstructured":"Sekaran CB, Rani AP. Development and validation of spectrophotometric method for the determination of DPP-4 inhibitor, sitagliptin, in its pharmaceutical preparations. J Eclet Qu\u00edm. 2010;35:45\u201353. https:\/\/doi.org\/10.1590\/S0100-46702010000300003.","journal-title":"J Eclet Qu\u00edm"},{"issue":"1","key":"1935_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/bio.70404","volume":"41","author":"TZ Attia","year":"2026","unstructured":"Attia TZ, Shahin RY, Taha HM, Noureldeen DA. Simple and novel fluorimetric protocol for sitagliptin estimation through sensitivity enhancement using acetic acid: application to pharmaceutical dosage form with green assessment. J Lumin. 2026;41(1):e70404. https:\/\/doi.org\/10.1002\/bio.70404.","journal-title":"J Lumin"},{"issue":"5","key":"1935_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/1573412913666170906164249","volume":"14","author":"MF Bakr Ali","year":"2018","unstructured":"Bakr Ali MF, Atia NN. Sensitive spectrofluorimetric methods for determination of sitagliptin phosphate, dipeptidyl peptidase-4 inhibitor, in pharmaceutical tablets and spiked human urine. J Curr Pharm Anal. 2018;14(5):483\u201390. https:\/\/doi.org\/10.2174\/1573412913666170906164249.","journal-title":"J Curr Pharm Anal"},{"issue":"3","key":"1935_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/157341212801619270","volume":"8","author":"S Caglar","year":"2012","unstructured":"Caglar S, Onal A, Toker S. Determination of sitagliptin with fluorescamine in tablets and spiked serum samples by spectrofluorimetry and a degradation study. J Curr Pharm Anal. 2012;8(3):278\u201385. https:\/\/doi.org\/10.2174\/157341212801619270.","journal-title":"J Curr Pharm Anal"},{"issue":"6","key":"1935_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/bio.4502","volume":"38","author":"MA El Hamd","year":"2023","unstructured":"El Hamd MA, Soltan OM, Abdelrahman KS, Alsaggaf WT, Abu-hassan AA. A new application of isoindole fluorophore derivative in sitagliptin antidiabetic medication assay: application to dosage forms and biological fluid evaluation. J Lumin. 2023;38(6):744\u201352. https:\/\/doi.org\/10.1002\/bio.4502.","journal-title":"J Lumin"},{"issue":"1","key":"1935_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.31838\/ijpr\/2020.SP1.269","volume":"12","author":"AJ SALEEM","year":"2020","unstructured":"SALEEM AJ, AL-AWADIE NS, J. I. New developed method for determination and detecting of Sitagliptin Phosphate via the use of ISNAG\u2013fluorimeter instrument. Int J Pharm Res. 2020;12(1):269\u201375. https:\/\/doi.org\/10.31838\/ijpr\/2020.SP1.269.","journal-title":"Int J Pharm Res"},{"issue":"8","key":"1935_CR50","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1007\/s11696-021-01646-3","volume":"75","author":"MM Elhassan","year":"2021","unstructured":"Elhassan MM, Mahmoud AM, Hegazy MA, Mowaka S. In-line monitoring of sitagliptin dissolution profile from tablets utilizing an eco-friendly potentiometric sensor. J Chem Pap. 2021;75(8):4165\u201376. https:\/\/doi.org\/10.1007\/s11696-021-01646-3.","journal-title":"J Chem Pap"},{"issue":"13","key":"1935_CR51","doi-asserted-by":"publisher","DOI":"10.1149\/1945-7111\/abbb43","volume":"167","author":"A G\u00f3rska","year":"2020","unstructured":"G\u00f3rska A, Paczosa-Bator B, Piech RJ. Highly sensitive adsorptive stripping voltammetric method for sitagliptin determination on renewable amalgam film electrode. J Electrochem Soc. 2020;167(13):136510. https:\/\/doi.org\/10.1149\/1945-7111\/abbb43.","journal-title":"J Electrochem Soc"},{"issue":"14","key":"1935_CR52","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1039\/D1NA00194A","volume":"3","author":"I Haq","year":"2021","unstructured":"Haq I, Alanazi K, Czulak J, Di Masi S, Piletska E, Mujahid A, et al. Determination of sitagliptin in human plasma using a smart electrochemical sensor based on electroactive molecularly imprinted nanoparticles. Nanoscale Adv. 2021;3(14):4276\u201385. https:\/\/doi.org\/10.1039\/D1NA00194A.","journal-title":"Nanoscale Adv"},{"issue":"8","key":"1935_CR53","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.52711\/0974-360X.2023.00612","volume":"16","author":"A Dwivedi","year":"2023","unstructured":"Dwivedi A, Sharma RJR. Development and Validation of Simultaneous Equation Method for Estimation of Sitagliptin Phosphate and Empagliflozin in bulk form by UV Spectroscopy. Res J Pharm Technol. 2023;16(8):3714\u20138. https:\/\/doi.org\/10.52711\/0974-360X.2023.00612.","journal-title":"Res J Pharm Technol"},{"issue":"3","key":"1935_CR54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.69613\/z7svx946","volume":"3","author":"SA Ahmed","year":"2025","unstructured":"Ahmed SA, Puri HKJ. Development and Validation of a Rapid RP-HPLC Method for Simultaneous Estimation of Empagliflozin and Sitagliptin Phosphate in Pharmaceutical Formulations. J Pharma Insight Res. 2025;3(3):286\u201394. https:\/\/doi.org\/10.69613\/z7svx946.","journal-title":"J Pharma Insight Res"},{"key":"1935_CR55","doi-asserted-by":"publisher","first-page":"1129092","DOI":"10.1155\/jspe\/1129092","volume":"1","author":"IOJ Abu Reid","year":"2026","unstructured":"Abu Reid IOJ. UV-Vis Spectrophotometric Determination of Multicomponent Pharmaceuticals: Limitations, Severity\u2010Driven Strategies, and Method Selection. J Spectrosc. 2026;1:1129092. https:\/\/doi.org\/10.1155\/jspe\/1129092.","journal-title":"J Spectrosc"},{"key":"1935_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.48175\/IJARSCT-9017","volume":"3","author":"A Bhalerao","year":"2023","unstructured":"Bhalerao A, Shelke MS, Borkar VJI. Advances, applications, and challenges in RP HPLC method development. Int J Adv Res Sci Commun Technol. 2023;3:111\u201323. https:\/\/doi.org\/10.48175\/IJARSCT-9017.","journal-title":"Int J Adv Res Sci Commun Technol"},{"issue":"1","key":"1935_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-025-01414-4","volume":"19","author":"HH Abuseada","year":"2025","unstructured":"Abuseada HH, Abdel Sattar OI, Madkour AW, Taha AS. A green three-ratio manipulating spectrophotometric approaches for the determination of a binary mixture of pantoprazole and domperidone. BMC Chem. 2025;19(1):57. https:\/\/doi.org\/10.1186\/s13065-025-01414-4.","journal-title":"BMC Chem"},{"issue":"2","key":"1935_CR58","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/jaoacint\/qsac128","volume":"106","author":"AH Abdelazim","year":"2023","unstructured":"Abdelazim AH, Abdel-Fattah A, Osman AO, Abdel-Kareem RF, Ramzy SJ. Spectrophotometric quantitative analysis of aspirin and vonoprazan fumarate in recently approved fixed-dose combination tablets using ratio spectra manipulating tools. AOAC Int. 2023;106(2):490\u20135. https:\/\/doi.org\/10.1093\/jaoacint\/qsac128.","journal-title":"AOAC Int"},{"key":"1935_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-019-0618-3","volume":"13","author":"CM El-Maraghy","year":"2019","unstructured":"El-Maraghy CM, Lamie NT. Three smart spectrophotometric methods for resolution of severely overlapped binary mixture of Ibuprofen and Paracetamol in pharmaceutical dosage form. BMC Chem. 2019;13:99. https:\/\/doi.org\/10.1186\/s13065-019-0618-3.","journal-title":"BMC Chem"},{"key":"1935_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-49144-4","volume":"16","author":"O Al kamaly","year":"2026","unstructured":"Al kamaly O, Sayedahmed M, Abdelzaher AM. Development and validation of ratio spectra manipulation methods for the determination of etoricoxib and tramadol in binary mixtures. Sci Rep. 2026;16:12875. https:\/\/doi.org\/10.1038\/s41598-026-49144-4.","journal-title":"Sci Rep"},{"issue":"1","key":"1935_CR61","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13065-024-01220-4","volume":"18","author":"HA Abdullatif","year":"2024","unstructured":"Abdullatif HA, Abdelkawy M, Kamal M, et al. Utilizing two different sustainable and green spectrophotometric approaches using derivative ratio spectra for the determination of a ternary severely overlapped mixture: application to veterinary formulation. BMC Chem. 2024;18:118. https:\/\/doi.org\/10.1186\/s13065-024-01220-4.","journal-title":"BMC Chem"},{"key":"1935_CR62","unstructured":"Guideline IHTJQ. Validation of analytical procedures: text and methodology. 2005;1(20):05."},{"key":"1935_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-026-01788-z","volume":"20","author":"AEF Abbas","year":"2026","unstructured":"Abbas AEF, Talib NFA, Elghobashy MR, Al Kamaly O, Halim MK. Candexch algorithm-enhanced chemometric determination of a novel anti-COVID-19 therapeutics in plasma and paxlovid formulation using advanced multivariate modeling: a sustainability-centered bioanalytical approach. BMC Chem. 2026;20:88. https:\/\/doi.org\/10.1186\/s13065-026-01788-z.","journal-title":"BMC Chem"},{"key":"1935_CR64","doi-asserted-by":"publisher","first-page":"117196","DOI":"10.1016\/j.trac.2023.117196","volume":"166","author":"LP Kowtharapu","year":"2023","unstructured":"Kowtharapu LP, Katari NK, Muchakayala SK, Marisetti VM. Green metric tools for analytical methods assessment critical review, case studies and crucify. TRAC. 2023;166:117196. https:\/\/doi.org\/10.1016\/j.trac.2023.117196.","journal-title":"TRAC"},{"issue":"1","key":"1935_CR65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13065-025-01486-2","volume":"19","author":"FR Mansour","year":"2025","unstructured":"Mansour FR, Nowak PM. Introducing the carbon footprint reduction index (CaFRI) as a software-supported tool for greener laboratories in chemical analysis. BMC Chem. 2025;19(1):121. https:\/\/doi.org\/10.1186\/s13065-025-01486-2.","journal-title":"BMC Chem"},{"key":"1935_CR66","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.greeac.2024.100126","volume":"10","author":"FR Mansour","year":"2024","unstructured":"Mansour FR, Omer KM, P\u0142otka-Wasylka J. A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness. Green Anal Chem. 2024;10:100126. https:\/\/doi.org\/10.1016\/j.greeac.2024.100126.","journal-title":"Green Anal Chem"},{"key":"1935_CR67","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.sampre.2025.100164","volume":"14","author":"FR Mansour","year":"2025","unstructured":"Mansour FR, Bedair A, Locatelli M. Click analytical chemistry index as a novel concept and framework, supported with open source software to assess analytical methods. Adv Sample Prep. 2025;14:100164. https:\/\/doi.org\/10.1016\/j.sampre.2025.100164.","journal-title":"Adv Sample Prep"},{"issue":"19","key":"1935_CR68","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1039\/D3GC02347H","volume":"25","author":"N Manousi","year":"2023","unstructured":"Manousi N, Wojnowski W, P\u0142otka-Wasylka J, Samanidou V. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality. Green Chem. 2023;25(19):7598\u2013604. https:\/\/doi.org\/10.1039\/D3GC02347H.","journal-title":"Green Chem"},{"issue":"1","key":"1935_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/analytica7010019","volume":"7","author":"FR Mansour","year":"2026","unstructured":"Mansour FR, Locatelli M, Obaydo RH, Farag AS, Bedair A. Whiteness evaluation for chemical analysis (WECA) as a flexible tool and web-based software for whiteness assessment in analytical chemistry. Analytica. 2026;7(1):19. https:\/\/doi.org\/10.3390\/analytica7010019.","journal-title":"Analytica"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-026-01935-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-026-01935-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-026-01935-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:48:49Z","timestamp":1790855329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13065-026-01935-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1935"],"URL":"https:\/\/doi.org\/10.1186\/s13065-026-01935-6","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.\u00a0","order":1,"name":"Ethics","label":"<b>Ethics approval and c<\/b>onsent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"198"}}